Abstract 17620: Incremental Values of Biomarkers for Predicting Incident Peripheral Vascular Disease Events in Patients With Established Coronary Artery Diseases
Background: Conventional clinical risk factors have modest sensitivity and specificity in predicting the occurrence of peripheral vascular disease (PVD). We sought to determine the role of different biomarkers, whether alone or in combination, exhibit incremental value for prediction of PVD.
Methods and Results: Serum adiponectin, adipocytes fatty acid binding protein 4 (A-FABP4), fibroblast growth factor (FGF)-19 and 21, lipocalcin-2 (LCN2) levels were measured in 1289 Chinese subjects with established coronary artery disease (CAD). After a median of 36.2 months follow-up, 15 patients (incidence, 2.5 per 1000 patient-years) developed new onset of symptomatic PVD requiring treatment. Among them, serum FGF-21, LCN2 and A-FABP4 provided better prediction than others with area under the receiver operating characteristic curves were 0.824 (95% CI, 0.728-0.920), 0.829 (95% CI, 0.730-0.927) and 0.826 (95% CI, 0.729-0.922) respectively after adjusting for clinical risk factors for PVD (all p<0.001). Kaplan-Meier analyses revealed significantly higher probabilities of PVD in the presence of high levels of FGF21, LCN2 and A-FABP (log-rank test, all p<0.001, Figure 1). Based on the optimal cutoff values, C-statistics of FGF-21, LCN2 and A-FABP4 were 0.831, 0.865 and 0.850, respectively, which further increased to 0.868 using a combination of LCN2 and A-FABP4 (Figure 2).
Conclusion: Our results demonstrated that elevated circulating FGF21, LCN2 and A-FABP levels can improve the prediction of incident peripheral vascular disease events beyond clinical risk factors in Chinese subjects with CAD, and the combination of LCN2 and A-FABP can provide the best prediction value.
Author Disclosures: Y. Wong: None. C.Y. Cheung: None. K. Au: None. S. Hong: None. C. Lee: None. J.S. Hai: None. K. Lau: None. T. Lam: None. P. Sham: None. A. Xu: None. K.S. Lam: None. H. Tse: None.
- © 2016 by American Heart Association, Inc.